Novo Nordisk’s 5.27 Billion Kroner Buyback and UK Pill Nod Trump Cyber Setback
Published on 06/15/2026 at 15:32 | Redaktion boerse-global.de
Novo Nordisk is deploying its balance sheet to send a message of confidence even as headwinds accumulate. The Danish pharma group has spent 5.27 billion Danish kroner since February repurchasing nearly 20 million B-shares, deploying roughly a third of a 15 billion kroner programme. The buys come as the stock trades 42% below last summer’s record high, offering management a chance to lock in discounted equity while signalling that the business’s underlying strength remains intact.
The share price has responded, climbing roughly 8% over the past week to 38.57 euros. That still leaves it below the 200-day moving average at 41.39 euros, but the rally has been underpinned by a series of positive catalysts. Among the most significant is the UK approval of an oral version of Wegovy, the blockbuster obesity drug. The pill formulation has shown a weight loss of nearly 17% in clinical studies, comfortably ahead of the roughly 12% delivered by Eli Lilly’s competing product.
Eli Lilly recently launched its own obesity medicine, Foundayo, ratcheting up the rivalry. Yet Wegovy continues to dominate in the prescription data: since the US launch, doctors have written more than 3 million scripts, and in April alone Novo Nordisk recorded 116,000 new weekly prescriptions – a pace that leaves Lilly trailing. The company’s international business grew 44% on a currency-adjusted basis in the first quarter, with Asia-Pacific surging 87%, though China contracted.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The pipeline also offers new reasons for optimism. On the sidelines of a medical conference in New Orleans, Novo Nordisk presented phase II data for Zenagamtide, a type 2 diabetes candidate that produced significant reductions in both blood sugar and body weight. A pivotal phase III trial is scheduled to begin in the second half of the year. Meanwhile, management is due to unveil new AI tools on Tuesday aimed at accelerating drug development.
Not all news has been constructive. On 11 June, unknown attackers breached internal systems and copied pseudonymised patient data from clinical studies, including birth years, gender and health details, along with contact information for medical staff. Novo Nordisk took the affected systems offline immediately and brought in external experts to investigate, stressing that core operations were unaffected. The incident had little visible impact on the stock, which closed the previous Friday at 38.03 euros before the buyback-driven rebound.
Pricing pressure remains a persistent challenge. In the United States, net prices are falling, and patents for key products are expiring in markets such as China and Brazil. Novo Nordisk now expects full-year revenue to decline by a maximum of 12% in currency-adjusted terms – an improvement from the previous forecast of 13%, thanks to robust GLP-1 sales. The stock has lost roughly 15% year to date, and the relative strength index sits near 54, indicating neutral territory.
A key test looms on 1 July, when a new Medicare programme in the US will give eligible patients access to obesity drugs for a fixed copay of $50. The move should boost prescription volumes, but investors are watching closely to see how it affects net pricing. With a buyback programme still two-thirds unused, a fresh UK approval for oral Wegovy, and a pipeline that keeps delivering, Novo Nordisk has multiple levers to pull – even as hackers and competition try to throw it off balance.
Ad
Novo Nordisk Stock: New Analysis - 15 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
